FDA approves Gilotrif for first-line, non-resistant EGFR-mutant NSCLC

FDA approved an sNDA from Boehringer Ingelheim GmbH (Ingelheim, Germany) for Gilotrif afatinib to include first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations. The product is already approved for first-line treatment of metastatic NSCLC in patients whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and to treat metastatic squamous NSCLC that has progressed after platinum-based chemotherapy...